IP Library › Granted Patent US 11,492,600
Granted Patent B2
US 11,492,600 · App. 16/562,497 · Granted Nov 8, 2022

Methods and products for transfection

Inventors: Matthew Angel (Cambridge, MA); Christopher Rohde (Cambridge, MA)
Assignee: Factor Bioscience Inc.
C12N5/0696C12N5/0625C12N5/0647C12N5/0656C12N5/0657C12N5/0676C12N5/0695C12N5/0018C12N2500/25C12N2500/33C12N2500/36C12N2500/84C12N2501/602C12N2501/603C12N2501/604C12N2501/606C12N2501/608C12N2501/998C12N2506/09C12N2506/45
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,492,600
App. No.
16/562,497
Granted
Nov 8, 2022
Kind
B2
Abstract

The present invention relates in part to methods for producing tissue-specific cells from patient samples, and to tissue-specific cells produced using these methods. Methods for reprogramming cells using RNA are disclosed. Therapeutics comprising cells produced using these methods are also disclosed.

Claims (28)

1. A method for reprogramming a differentiated cell to a less differentiated state, comprising:

(a) providing a differentiated cell;

(b) culturing the differentiated cell; and

(c) transfecting the differentiated cell with one or more synthetic RNA molecules,

wherein the one or more synthetic RNA molecules include at least one RNA molecule encoding one or more reprogramming factors selected from the group consisting of Oct4 protein, Sox2 protein, Klf4 protein, c-Myc protein, 1-Myc protein, Tert protein, Nanog protein, and Lin28 protein;

wherein the transfecting results in the cell expressing the one or more reprogramming factors to result in the cell being reprogrammed to a less differentiated state; and

wherein step (c) is performed not in the presence of irradiated fibroblast feeder cells and occurs in the presence of a medium containing ingredients that support reprogramming of the differentiated cell to a less differentiated state.

2. The method of claim 1 , wherein the differentiated cell is derived from a biopsy.

3. The method of claim 2 , wherein the differentiated cell is derived from a dermal punch biopsy sample.

4. The method of claim 1 , wherein the differentiated cell is from a human subject.

5. The method of claim 1 , wherein the differentiated cell is a skin cell.

6. The method of claim 1 , further comprising contacting the cell with at least one member of the group: poly-L-lysine, poly-L-ornithine, RGD peptide, fibronectin, vitronectin, collagen, and laminin.

7. The method of claim 1 , wherein the one or more synthetic RNA molecules contain at least one of a pseudouridine or a 5-methylcytidine residue.

8. The method of claim 1 , wherein the medium is substantially free of immunosuppressants.

9. A method for reprogramming a non-pluripotent cell, comprising:

(a) providing a non-pluripotent cell;

(b) culturing the non-pluripotent cell; and

(c) transfecting the non-pluripotent cell with one or more synthetic RNA molecules,

wherein the one or more synthetic RNA molecules include at least one RNA molecule encoding one or more reprogramming factors selected from the group consisting of Oct4 protein, Sox2 protein, Klf4 protein, c-Myc protein, 1-Myc protein, Tert protein, Nanog protein, and Lin28 protein;

wherein the transfecting results in the cell expressing the one or more reprogramming factors to result in the cell being reprogrammed; and

wherein step (c) is performed not in the presence of irradiated fibroblast feeder cells and occurs in the presence of a medium containing ingredients that support reprogramming of the non-pluripotent cell.

10. The method of claim 9 , wherein the non-pluripotent cell is derived from a biopsy.

11. The method of claim 10 , wherein the non-pluripotent cell is derived from a dermal punch biopsy sample.

12. The method of claim 9 , wherein the non-pluripotent cell is from a human subject.

13. The method of claim 9 , wherein the non-pluripotent cell is a skin cell.

14. The method of claim 9 , further comprising contacting the cell with at least one member of the group: poly-L-lysine, poly-L-ornithine, RGD peptide, fibronectin, vitronectin, collagen, and laminin.

15. The method of claim 9 , wherein the one or more synthetic RNA molecules contain at least one of a pseudouridine or a 5-methylcytidine residue.

16. The method of claim 9 , wherein the medium is substantially free of immunosuppressants.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 2, 2019
From: ANGEL, MATTHEW; ROHDE, CHRISTOPHER
To: FACTOR BIOSCIENCE INC.
Reel/Frame 051148/0394 →
Continuity (14)
Continuation 16374482 · Apr 3, 2019
Continuation 16037597 · Jul 17, 2018
Continuation 15947741 · Apr 6, 2018
Continuation 15844063 · Dec 15, 2017
Continuation 15605513 · May 25, 2017
Continuation 15358818 · Nov 22, 2016
Continuation 15178190 · Jun 9, 2016
Continuation 14810123 · Jul 27, 2015
Continuation 13931251 · Jun 28, 2013
Continuation 13465490 · May 7, 2012
Provisional Application 61637570 · Apr 24, 2012
Provisional Application 61569595 · Dec 12, 2011
Provisional Application 61566948 · Dec 5, 2011
Related Publication 20200048616A1 · Feb 13, 2020
Cited By (1)
US 12,227,768